The transient receptor potential channel vanilloid subfamily V member 3 (TRPV3), which functions as a thermosensor in keratinocytes, plays an important role in the development of allergic and itchy dermatitis in rodents. Although real-time PCR analysis using lesional and non-lesional skin samples from patients with atopic dermatitis showed that TRPV3 was expressed in lesional skin, the role that TRPV3 plays in patients with dermatitis is still relatively obscure. Here, we determined whether TRPV3 was a dendritic cell (DC) modulator using DS-Nh mice with a gain-of-function mutation in TRPV3 (TRPV3Gly573Ser), because increasing skin temperature is associated with the modulation of dermal dendritic cells (DCs). Interestingly, increased responses to haptens by skin and DCs were observed in DS-Nh mice compared with those from DS mice with wild-type TRPV3. Increased thymic stromal lymphopoietin (TSLP) responses were also observed in keratinocytes from DS-Nh mice compared with those from DS mice. Taken together, we propose that the DS-Nh mouse is a good model to use in order to better understand the role of this orphan channel and that TRPV3 may represent a new therapeutic target in certain types of dermatitis through the control of DCs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/exd.12273 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of TRPV3 on the development of allergic dermatitis as a dendritic cell modulator.
Exp Dermatol
December 2013
Department of Biology, Graduate School of Science, Kobe University, Kobe, Japan; Shionogi Medicinal Research Laboratories, Shionogi & Co., Ltd., Osaka, Japan.
The transient receptor potential channel vanilloid subfamily V member 3 (TRPV3), which functions as a thermosensor in keratinocytes, plays an important role in the development of allergic and itchy dermatitis in rodents. Although real-time PCR analysis using lesional and non-lesional skin samples from patients with atopic dermatitis showed that TRPV3 was expressed in lesional skin, the role that TRPV3 plays in patients with dermatitis is still relatively obscure. Here, we determined whether TRPV3 was a dendritic cell (DC) modulator using DS-Nh mice with a gain-of-function mutation in TRPV3 (TRPV3Gly573Ser), because increasing skin temperature is associated with the modulation of dermal dendritic cells (DCs).
View Article and Find Full Text PDFSpecific substance of Maruyama (SSM) suppresses immune responses in atopic dermatitis-like skin lesions in DS-Nh mice by modulating dendritic cell functions.
J Dermatol Sci
September 2011
Department of Dermatology, Nippon Medical School, 1-1-5 Sendagi, Bunkyou-ku, Tokyo 113-8603, Japan.
Background: Specific substance of Maruyama (SSM) is a carcinostatic immunotherapeutic agent extracted from Mycobacterium tuberculosis. The efficacy of SSM induced interleukin(IL)-12 and IFN-γ production, and inhibition of IL-4, resulting in a shift from Th2 to Th1 in vivo.
Objective: The DS-Nh mice are a model of human atopic dermatitis (AD), which spontaneously develop dermatitis under conventional conditions.
A Role of Staphyococcus aureus, Interleukin-18, Nerve Growth Factor and Semaphorin 3A, an Axon Guidance Molecule, in Pathogenesis and Treatment of Atopic Dermatitis.
Allergy Asthma Immunol Res
October 2010
Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Article Synopsis
- Staphylococcus aureus (SA) is commonly found in skin lesions of atopic dermatitis (AD) and contributes to the disease's progression by releasing toxins that activate skin cells and increase levels of IL-18, leading to inflammation.
- Research shows a significant correlation between SA colony counts on the skin and IL-18 levels, linking these factors to the severity of AD in both human patients and DS-Nh mice, which serve as a model for studying the disease.
- CD25 +CD4 + regulatory T cells are identified as potentially key players in reducing AD symptoms by suppressing Th1 cell responses induced by IL-18, indicating a new avenue for AD treatment, particularly in the context of treatments affecting immune regulation.
Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment:mouse models for the development of remedies for human allergic dermatitis.
J Pharmacol Sci
July 2009
Laboratory of Pharmacology, Department of Bioactive Molecules, Gifu Pharmaceutical University, Japan.
Animal models for human diseases are important for the elucidation of mechanisms involved in as well as for the establishment of effective treatment strategies for the diseases. Many mouse allergic dermatitis models have been established and applied for the development of remedies for human allergic dermatitis. One of the simplest allergic cutaneous reaction models is passive cutaneous anaphylaxis.
View Article and Find Full Text PDFDNA vaccination against macrophage migration inhibitory factor improves atopic dermatitis in murine models.
J Allergy Clin Immunol
July 2009
Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan.
Article Synopsis
- Atopic dermatitis (AD) is a common inflammatory skin condition, and recent research has focused on using a novel DNA vaccine that targets macrophage migration inhibitory factor (MIF), a protein involved in AD.
- The study tested this MIF-DNA vaccine in mouse models, finding that it not only prevented the onset of AD but also improved symptoms in mice that already had the condition.
- Results indicated that vaccinated mice showed less skin inflammation and lower levels of a specific antibody (IgE) linked to allergies, suggesting that the MIF-DNA vaccine could be a promising treatment for AD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!